2.29
+0.2(+9.57%)
Currency In USD
| Previous Close | 2.09 |
| Open | 2.14 |
| Day High | 2.34 |
| Day Low | 2.13 |
| 52-Week High | 16.71 |
| 52-Week Low | 1.91 |
| Volume | 265,865 |
| Average Volume | 96,057 |
| Market Cap | 10.4M |
| PE | -0.25 |
| EPS | -9.16 |
| Moving Average 50 Days | 2.2 |
| Moving Average 200 Days | 4.99 |
| Change | 0.2 |
If you invested $1000 in IN8bio, Inc. (INAB) since IPO date, it would be worth $229 as of September 29, 2025 at a share price of $2.29. Whereas If you bought $1000 worth of IN8bio, Inc. (INAB) shares 3 years ago, it would be worth $1,162.44 as of September 29, 2025 at a share price of $2.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
GlobeNewswire Inc.
Jun 09, 2025 11:00 AM GMT
Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trialNEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8b
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
GlobeNewswire Inc.
Jun 02, 2025 11:30 AM GMT
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is well-tolerated, showing no ser
IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025
GlobeNewswire Inc.
May 14, 2025 12:00 PM GMT
Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune diseases Innovative Next Generation TCE Platform: